Although SRI-5 response rates were not significantly improved in the pooled blisibimod groups compared with placebo , they were higher in subjects randomised to the highest dose of blisibimod ( 200mg once-weekly ( QW ) ) compared with pooled placebo , from Week 16 to Week 24 , reaching statistical significance at Week 20 ( p = 0.02 ) .